ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Mountain Crest Acquisition Corporation II

Mountain Crest Acquisition Corporation II (MCAD)

10,43
0,00
(0,00%)
Geschlossen 24 November 10:00PM
0,00
0,00
(0,00%)
Nach Börsenschluss: -

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Current Price
10,43
Gebot
10,30
Fragen
10,42
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Handelsende
10,43
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Durchschnittliches Volumen (3 Mio.)
-
Finanzvolumen
-
VWAP
-

MCAD Neueste Nachrichten

Better Therapeutics Closes Business Combination and Debuts on Nasdaq

Trading to commence on Nasdaq on Oct. 29, 2021, under the ticker symbol BTTX Better Therapeutics, Inc., a prescription digital therapeutics (PDT) company delivering cognitive behavioral therapy...

Mountain Crest Acquisition Corp. II Stockholders Approve Business Combination with Better Therapeutics Inc.

NEW YORK, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ: MCAD) (the “Company”), a publicly traded special purpose acquisition company, announced today that in a...

Mountain Crest Acquisition Corp. II and Better Therapeutics, Inc. Announce Registration Statement Effectiveness and Scheduled Special Meeting to Approve Business Combination on October 27, 2021

NEW YORK and SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ: MCAD, “Mountain Crest II”), a publicly-traded special purpose acquisition company and...

Better Therapeutics to Participate in Lake Street’s 5th Annual Best Ideas Growth (BIG5) Conference on September 14-15, 2021

Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases...

Better Therapeutics Highlights Recent Progress and Updates Outlook Through 2022

Pivotal trial of BT-001 in type 2 diabetes expected to be fully enrolled in Q4 2021, with primary endpoint readout in Q1 2022; de novo submission to FDA requesting marketing authorization planned...

Better Therapeutics Expands Real-World Evidence Study Initiative With Addition of Catalyst Health Network

Open-label, real-world study will evaluate BT-001’s cognitive behavioral therapy approach to change behaviors at the root cause of type 2 diabetes Study to evaluate the durability of treatment...

Better Therapeutics Launches Real World Evidence Study of Prescription Digital Therapeutic for Type 2 Diabetes

Open-label, non-randomized, controlled study will span one year and evaluate BT-001’s cognitive behavioral therapy approach to change behaviors at root cause of type 2 diabetes Study to evaluate...

Better Therapeutics to Become Publicly Traded Prescription Digital Therapeutics Company via Merger with Mountain Crest Acquis...

Transaction values Better Therapeutics at a pro forma fully diluted enterprise value of approximately $187 million with existing Better Therapeutics shareholders rolling over 100% of their equity...

Mountain Crest Acquisition Corp. II Announces that Common Stock and Rights to Commence Separate Trading on or about March 17,...

New York, N.Y., March 15, 2021 (GLOBE NEWSWIRE) -- March 15, 2021 Mountain Crest Acquisition Corp. II (the “Company”) (NASDAQ: MCADU), a blank check company formed for the purpose of entering...

Mountain Crest Acquisition Corp. II Announces Closing of Fully-Exercised Over-Allotment Option in Connection with Its Initial...

New York, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ: MCADU, the “Company”) announced today that the underwriters in its initial public offering, pursuant to...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
PDYNPalladyne AI Corporation
US$ 4,59
(129,50%)
83,07M
QMCOQuantum Corporation
US$ 9,11
(126,62%)
39,48M
NANano Labs Ltd
US$ 8,26
(89,02%)
2,03M
XCURExicure Inc
US$ 18,60
(71,27%)
4,59M
SKKSKK Holdings Limited
US$ 1,75
(59,09%)
107,47M
AMIXAutonomix Medical Inc
US$ 6,21
(-54,07%)
946,09k
CETXCemtrex Inc
US$ 0,1146
(-41,74%)
24,39M
MSWMing Shing Group Holdings Ltd
 5,90
(-35,52%)
417,08k
RMSGReal Messenger Corporation
US$ 3,09
(-26,25%)
313,51k
ENSCEnsysce Biosciences Inc
US$ 0,4414
(-25,49%)
4M
ELABElevai Labs Inc
US$ 0,0201
(-0,50%)
425,38M
NVDANVIDIA Corporation
US$ 141,95
(-3,22%)
236,51M
SMCISuper Micro Computer Inc
US$ 33,15
(11,62%)
159,61M
VRPXVirpax Pharmaceuticals Inc
US$ 0,5501
(-6,72%)
159,39M
SOUNSoundHound AI Inc
US$ 8,24
(18,05%)
107,91M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock